Aspirin and mortality from coronary bypass surgery

被引：472

作者：

Mangano, DT ^{[1
]}

Saidman, L ^{[1
]}

Levin, J ^{[1
]}

Barash, P ^{[1
]}

Dietzel, C ^{[1
]}

Herskowitz, A ^{[1
]}

Ley, C ^{[1
]}

Hsu, P ^{[1
]}

Kardatzke, D ^{[1
]}

Wang, S ^{[1
]}

Tudor, IC ^{[1
]}

Beatty, D ^{[1
]}

Xavier, B ^{[1
]}

Kerkela, S ^{[1
]}

Aronson, S ^{[1
]}

Comunale, M ^{[1
]}

D'Ambra, M ^{[1
]}

Eaton, M ^{[1
]}

Engelman, R ^{[1
]}

Fitch, J ^{[1
]}

Grichnik, K ^{[1
]}

Hantler, CB ^{[1
]}

Hillel, Z ^{[1
]}

Kanchuger, M ^{[1
]}

Ostrowski, J ^{[1
]}

Mangano, CM ^{[1
]}

Mathew, J ^{[1
]}

Fontes, M ^{[1
]}

Barash, P ^{[1
]}

McSweeney, M ^{[1
]}

Wolman, R ^{[1
]}

Napolitano, CA ^{[1
]}

Nesbitt, LA ^{[1
]}

Nijhawan, N ^{[1
]}

Nussmeier, N ^{[1
]}

Pivalizza, EG ^{[1
]}

Polson, S ^{[1
]}

Ramsay, J ^{[1
]}

Roach, G ^{[1
]}

Schwann, N ^{[1
]}

Shenaq, S ^{[1
]}

Shevde, K ^{[1
]}

Shore-Lesserson, L ^{[1
]}

Bronheim, D ^{[1
]}

Wahr, J ^{[1
]}

Spiess, B ^{[1
]}

Wallace, A ^{[1
]}

Metzler, H ^{[1
]}

Ansley, D ^{[1
]}

O'Connor, JP ^{[1
]}

机构：

[1] Ischemia Res & Educ Fdn, Editorial Off, San Francisco, CA 94134 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2002年 / 347卷 / 17期

关键词：

D O I：

10.1056/NEJMoa020798

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: There is no therapy known to reduce the risk of complications or death after coronary bypass surgery. Because platelet activation constitutes a pivotal mechanism for injury in patients with atherosclerosis, we assessed whether early treatment with aspirin could improve survival after coronary bypass surgery. Methods: At 70 centers in 17 countries, we prospectively studied 5065 patients undergoing coronary bypass surgery, of whom 5022 survived the first 48 hours after surgery. We gathered data on 7500 variables per patient and adjudicated outcomes centrally. The primary focus was to discern the relation between early aspirin use and fatal and nonfatal outcomes. Results: During hospitalization, 164 patients died (3.2 percent), and 812 others (16.0 percent) had nonfatal cardiac, cerebral, renal, or gastrointestinal ischemic complications. Among patients who received aspirin (up to 650 mg) within 48 hours after revascularization, subsequent mortality was 1.3 percent (40 of 2999 patients), as compared with 4.0 percent among those who did not receive aspirin during this period (81 of 2023, P<0.001). Aspirin therapy was associated with a 48 percent reduction in the incidence of myocardial infarction (2.8 percent vs. 5.4 percent, P<0.001), a 50 percent reduction in the incidence of stroke (1.3 percent vs. 2.6 percent, P=0.01), a 74 percent reduction in the incidence of renal failure (0.9 percent vs. 3.4 percent, P<0.001), and a 62 percent reduction in the incidence of bowel infarction (0.3 percent vs. 0.8 percent, P=0.01). Multivariate analysis showed that no other factor or medication was independently associated with reduced rates of these outcomes and that the risk of hemorrhage, gastritis, infection, or impaired wound healing was not increased with aspirin use (odds ratio for these adverse events, 0.63; 95 percent confidence interval, 0.54 to 0.74). Conclusions: Early use of aspirin after coronary bypass surgery is safe and is associated with a reduced risk of death and ischemic complications involving the heart, brain, kidneys, and gastrointestinal tract.

引用

页码：1309 / 1317

页数：9

共 44 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2] ASSOCIATION BETWEEN GASTRIC INTRAMUCOSAL PH AND SPLANCHNIC ENDOTOXIN, ANTIBODY TO ENDOTOXIN, AND TUMOR-NECROSIS-FACTOR-ALPHA CONCENTRATIONS IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS [J].

ANDERSEN, LW ;

LANDOW, L ;

BAEK, L ;

JANSEN, E ;

BAKER, S .

CRITICAL CARE MEDICINE, 1993, 21 (02) :210-217

[3]

[Anonymous], 2002, **DROPPED REF**

[4]

[Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]

[5]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[6]

BAUMGARTNER WA, 1994, J HOPKINS MANUAL CAR

[7] Molecular and cellular mechanisms of myocardial stunning [J].

Bolli, R ;

Marbán, E .

PHYSIOLOGICAL REVIEWS, 1999, 79 (02) :609-634

[8] ACUTE MYOCARDIAL DYSFUNCTION AND RECOVERY - A COMMON OCCURRENCE AFTER CORONARY-BYPASS SURGERY [J].

BREISBLATT, WM ;

STEIN, KL ;

WOLFE, CJ ;

FOLLANSBEE, WP ;

CAPOZZI, J ;

ARMITAGE, JM ;

HARDESTY, RL .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (06) :1261-1269

[9] EFFECT OF DIPYRIDAMOLE AND ASPIRIN ON LATE VEIN-GRAFT PATENCY AFTER CORONARY-BYPASS OPERATIONS [J].

CHESEBRO, JH ;

FUSTER, V ;

ELVEBACK, LR ;

CLEMENTS, IP ;

SMITH, HC ;

HOLMES, DR ;

BARDSLEY, WT ;

PLUTH, JR ;

WALLACE, RB ;

PUGA, FJ ;

ORSZULAK, TA ;

PIEHLER, JM ;

DANIELSON, GK ;

SCHAFF, HV ;

FRYE, RL .

NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (04) :209-214

[10] Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].

Concato, J ;

Shah, N ;

Horwitz, RI .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892

← 1 2 3 4 5 →